206 related articles for article (PubMed ID: 25070180)
1. Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
Brix DM; Rafn B; Bundgaard Clemmensen K; Andersen SH; Ambartsumian N; Jäättelä M; Kallunki T
Mol Oncol; 2014 Dec; 8(8):1703-18. PubMed ID: 25070180
[TBL] [Abstract][Full Text] [Related]
2. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
[TBL] [Abstract][Full Text] [Related]
3. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
[TBL] [Abstract][Full Text] [Related]
4. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
7. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
8. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.
Rafn B; Nielsen CF; Andersen SH; Szyniarowski P; Corcelle-Termeau E; Valo E; Fehrenbacher N; Olsen CJ; Daugaard M; Egebjerg C; Bøttzauw T; Kohonen P; Nylandsted J; Hautaniemi S; Moreira J; Jäättelä M; Kallunki T
Mol Cell; 2012 Mar; 45(6):764-76. PubMed ID: 22464443
[TBL] [Abstract][Full Text] [Related]
9. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Li G; Wang X; Hibshoosh H; Jin C; Halmos B
PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
[TBL] [Abstract][Full Text] [Related]
10. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
11. LASP-1 interacts with ErbB2 in ovarian cancer cells.
Sidhanth C; Bindhya S; Shabna A; Krishnapriya S; Manasa P; Nagare RP; Joshua T; Sneha S; Murhekar K; Ganesan TS
Biochem J; 2022 Jan; 479(1):23-38. PubMed ID: 34881777
[TBL] [Abstract][Full Text] [Related]
12. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
13. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
[TBL] [Abstract][Full Text] [Related]
14. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
de Martino M; Zhuang D; Klatte T; Rieken M; Rouprêt M; Xylinas E; Clozel T; Krzywinski M; Elemento O; Shariat SF
Cancer Biol Ther; 2014 Sep; 15(9):1239-47. PubMed ID: 24971884
[TBL] [Abstract][Full Text] [Related]
15. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Kancha RK; von Bubnoff N; Bartosch N; Peschel C; Engh RA; Duyster J
PLoS One; 2011; 6(10):e26760. PubMed ID: 22046346
[TBL] [Abstract][Full Text] [Related]
17. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
19. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
[TBL] [Abstract][Full Text] [Related]
20. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]